Ns Pharma

NS Pharma, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare neuromuscular diseases, with a primary focus on Duchenne muscular dystrophy (DMD). It operates as a subsidiary of Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company with over a century of expertise in drug development. NS Pharma generates revenue through the research, approval, and sale of targeted therapies, such as its FDA-approved drug Viltepso (viltolarsen) for DMD treatment. The company emphasizes patient-centric solutions and collaboration with healthcare providers, reflecting its commitment to advancing rare disease treatment. Candidates should note its strong foundation in research and its global reach through its parent company.

Recent Posts by Ns Pharma

1-8 of 8